Flag of the Hong Kong

Hong Kong Health News API

Get the live top health headlines from Hong Kong with our JSON API.

Get API key for the Hong Kong Health News API

API Demonstration

This example demonstrates the HTTP request to make and the JSON response you will receive when you use the news api to get the top headlines from Hong Kong.

GET
https://gnews.io/api/v4/top-headlines?country=hk&category=health&apikey=API_KEY
{
    "totalArticles": 2238294,
    "articles": [
        {
            "title": "難治型濾泡性淋巴瘤治療選擇增添新解方 BTK抑制劑合併療法受關注",
            "description": "獨家報導 -",
            "content": "【健康醫療網/記者蘇靖昀報導】淋巴癌對於健康威脅不容小覷!國人近9成屬於非何杰金氏淋巴瘤,其中濾泡性淋巴瘤(FL,約15%)與邊緣區淋巴瘤(MZL,約10%)合計約占B細胞淋巴瘤25%,兩者皆屬於惰性淋巴瘤。因初期症狀不明顯,又多好發於60歲以上長者,使得診斷與治療困難度增加。馬偕紀念醫院血液腫瘤科張明志醫師指出,FL與MZL分別為第二﹑三常見的惰性淋巴瘤,患者得長期與疾病對抗共存。但長者對於傳統化學治療耐受力較差,且副作用明顯,隨著標靶藥物日新月異的發展,新一代口服標靶BTK抑制劑(BTKi)... [1781 chars]",
            "url": "https://www.scooptw.com/healthnews/377883/%E9%9B%A3%E6%B2%BB%E5%9E%8B%E6%BF%BE%E6%B3%A1%E6%80%A7%E6%B7%8B%E5%B7%B4%E7%98%A4%E6%B2%BB%E7%99%82%E9%81%B8%E6%93%87%E5%A2%9E%E6%B7%BB%E6%96%B0%E8%A7%A3%E6%96%B9%E3%80%80btk%E6%8A%91%E5%88%B6/",
            "image": "https://www.healthnews.com.tw/imageFile/202507/c6f60a16a27a4b33b17f37bb2e469db5.jpg",
            "publishedAt": "2025-07-03T01:30:00Z",
            "source": {
                "name": "獨家報導",
                "url": "https://www.scooptw.com"
            }
        },
        {
            "title": "難治型濾泡性淋巴瘤治療選擇增添新解方 BTK抑制劑合併療法受關注",
            "description": "【健康醫療網/記者蘇靖昀報導】淋巴癌對於健康威脅不容小覷!國人近9成屬於非何杰金氏淋巴瘤,其中濾泡性",
            "content": "【健康醫療網/記者蘇靖昀報導】淋巴癌對於健康威脅不容小覷!國人近9成屬於非何杰金氏淋巴瘤,其中濾泡性淋巴瘤(FL,約15%)與邊緣區淋巴瘤(MZL,約10%)合計約占B細胞淋巴瘤25%,兩者皆屬於惰性淋巴瘤。因初期症狀不明顯,又多好發於60歲以上長者,使得診斷與治療困難度增加。馬偕紀念醫院血液腫瘤科張明志醫師指出,FL與MZL分別為第二﹑三常見的惰性淋巴瘤,患者得長期與疾病對抗共存。但長者對於傳統化學治療耐受力較差,且副作用明顯,隨著標靶藥物日新月異的發展,新一代口服標靶BTK抑制劑(BTKi)... [1724 chars]",
            "url": "https://n.yam.com/Article/20250703590871",
            "image": "https://imagedelivery.net/UYQOTZcPn8gGeaNtnHVGeg/8e0fe484-1734-4fc6-b83a-eaa41ac0ef00/public",
            "publishedAt": "2025-07-03T01:30:00Z",
            "source": {
                "name": "蕃新聞",
                "url": "https://n.yam.com"
            }
        },
        {
            "title": "難治型濾泡性淋巴瘤治療選擇增添新解方 BTK抑制劑合併療法受關注",
            "description": "淋巴癌對於健康威脅不容小覷!國人近9成屬於非何杰金氏淋巴瘤,其中濾泡性淋巴瘤(FL,約15%)與邊緣區淋巴瘤(MZL,約10%)合計約占B細胞淋巴瘤25%,兩者皆屬於惰性淋巴瘤。因初期症狀不明顯,又多好發於60歲以上長者,使得診斷與治療困難度增加。馬偕紀念醫院血液腫瘤科張明志醫師指出,FL與MZL分別為第二﹑三常見的惰性淋巴瘤,患者得長期與疾病對抗共存。但長者對於傳統化學治療耐受力較差,且副作用明...",
            "content": "淋巴癌對於健康威脅不容小覷!國人近9成屬於非何杰金氏淋巴瘤,其中濾泡性淋巴瘤(FL,約15%)與邊緣區淋巴瘤(MZL,約10%)合計約占B細胞淋巴瘤25%,兩者皆屬於惰性淋巴瘤。因初期症狀不明顯,又多好發於60歲以上長者,使得診斷與治療困難度增加。馬偕紀念醫院血液腫瘤科張明志醫師指出,FL與MZL分別為第二﹑三常見的惰性淋巴瘤,患者得長期與疾病對抗共存。但長者對於傳統化學治療耐受力較差,且副作用明顯,隨著標靶藥物日新月異的發展,新一代口服標靶BTK抑制劑(BTKi)提供了高齡患者另一種、甚至是無... [1571 chars]",
            "url": "https://www.healthnews.com.tw/article/65550",
            "image": "https://www.healthnews.com.tw/imageFile/202507/2dc5de1855a12c85ceca4010f09aa3eb_l.jpg",
            "publishedAt": "2025-07-03T01:30:00Z",
            "source": {
                "name": "健康醫療網",
                "url": "https://www.healthnews.com.tw"
            }
        }
    ]
}

Categories